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Abstract
Background—Evidence shows underutilization of cancer genetics services. To explore the 
reasons behind this underutilization, this study evaluated characteristics of women who were 
referred for genetic counseling and/or had undergone BRCA1/2 testing.
Methods—An ovarian cancer risk perception study stratified 16,720 eligible women from the 
Henry Ford Health System into average-, elevated-, and high-risk groups based on family history. 
We randomly selected 3,307 subjects and interviewed 2,524 of them (76.3% response rate).
Results—Among the average-, elevated-, and high-risk groups, 2.3, 10.1, and 20.2%, 
respectively, reported genetic counseling referrals, and 0.8, 3.3, and 9.5%, respectively, reported 
having undergone BRCA testing. Personal breast cancer history, high risk, and perceived ovarian 
cancer risk were associated with both referral and testing. Discussion of family history with a 
doctor predicted counseling referral, whereas belief that family history influenced risk was the 
strongest BRCA testing predictor. Women perceiving their cancer risk as much higher than other 
women their age were twice as likely (95% confidence interval: 2.0–9.6) to report genetic 
counseling referral.
Conclusion—In a health system with ready access to cancer genetic counseling and BRCA 
testing, women who were at high risk underutilized these services. There were strong associations 
between perceived ovarian cancer risk and genetic counseling referral, and between a belief that 
family history influenced risk and BRCA testing.
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INTRODUCTION
Hereditary breast and ovarian cancer syndrome (HBOC), which is associated with the 
BRCA1 or BRCA2 (BRCA1/2) genes, accounts for an estimated 2–7% of breast cancers and 
10–15% of ovarian cancers. Approximately 1 in 400 individuals in the general population 
and 1 in 40 individuals of Ashkenazi Jewish descent have a mutation in BRCA1/2.1-3 
Lifetime risks for breast and ovarian cancer in women who carry BRCA1/2 mutations range 
from 40 to 80% and from 10 to 40%, respectively.4 First-degree relatives (male and female) 
of known mutation carriers have a 50% chance of inheriting the familial mutation. Earlier 
and more frequent cancer screening, use of breast magnetic resonance imaging, and surgical 
risk-reducing options, such as prophylactic mastectomy and bilateral salpingo-
oophorectomy, have shown clear potential for reducing cancer incidence and mortality and 
improving the likelihood of early detection for BRCA1/2 mutation carriers.5-7
Many groups, such as the National Comprehensive Cancer Network, the US Preventive 
Services Task Force, the American College of Obstetrics and Gynecology, and the National 
Society of Genetic Counselors, support the identification and appropriate management of 
BRCA mutation carriers and have published related guidelines.8-11 Moreover, a substantial 
proportion of health insurers cover the cost of BRCA testing for at-risk individuals, although 
genetic counseling is less consistently reimbursed.12 Despite the growing support of the 
medical and payer communities, and the availability of BRCA testing since 1996, it is 
estimated that most individuals who carry BRCA mutations remain unidentified.13
Although there is great interest in genetic testing among the general public,14 the low uptake 
of genetic counseling and testing for HBOC might be explained in part by barriers occurring 
at the patient, provider, and system levels.15 Factors known to pose challenges to both 
referral and utilization of cancer risk counseling and testing for BRCA1/2 mutations include 
cost and insurance coverage, provider awareness, race/ethnicity, concerns regarding 
insurance discrimination, and psychosocial barriers.16-18 The decision to undergo genetic 
counseling and testing is multifaceted and may be spurred by a desire to understand one’s 
own risk for cancer as well as risks for one’s children and other relatives.19,20 In addition, a 
personal experience with breast or ovarian cancer19 and a strong family history of 
cancer21,22 are significant motivators to seek cancer genetics services. A heightened 
perception of personal vulnerability to cancer, often resulting from an overestimation of 
personal risk,23,24 might also influence patient participation in genetic counseling and 
testing for HBOC.
Our study evaluates the frequency of genetic counseling referral and BRCA1/2 testing 
among women at average, elevated, and high risk based on family history of breast and 
ovarian cancer, as well as Ashkenazi ancestry, from a large integrated health system with 
both coverage for and ready access to these services. This analysis also explores individual-
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level characteristics that may affect genetic counseling referral and BRCA1/2 testing, and 
examines the influence of key aspects of family cancer history, sociodemographic 
characteristics, and risk perception factors on the uptake of cancer genetics services.
MATERIALS AND METHODS
Study population, eligibility criteria, and design
Data were obtained from a study conducted by the Centers for Disease Control and 
Prevention that evaluated ovarian cancer risk perception and screening among women in the 
Henry Ford Health System (HFHS), Detroit, Michigan. Detailed information on survey 
design and implementation has been previously published.25 Briefly, computer-assisted 
telephone interviews were conducted between 16 January and 13 December 2008 among 
eligible women ≥30 years of age, with no previous history of ovarian cancer or bilateral 
oophorectomy.
For random sampling purposes, we used responses from the eligibility screener to stratify 
women into three risk groups based on the number of first- and second-degree relatives with 
breast or ovarian cancer and personal history of breast cancer. HFHS administrative data 
identified 55,887 potential study participants; of these 20,483 underwent eligibility 
screening (36.7%) and 16,720 (81.6%) were deemed eligible. The computer-assisted 
telephone interview system randomly selected 3,307 women for participation in the study. 
Women in the elevated- and high-risk groups based on the eligibility screener were 
oversampled, and subsequent analyses were weighted. A total of 2,524 women gave consent 
and were interviewed, for a response rate of 76.3%.
The interview questions addressed detailed information about family history of cancer 
(including breast and ovarian) among first- and second-degree relatives in both maternal and 
paternal lineages, as well as age of diagnosis and the occurrence of bilateral breast cancer 
and male breast cancer, and Jewish ancestry. This additional information was used to assign 
women more accurately to average-, elevated-, and high-risk categories with regard to risk 
for breast and/or ovarian cancer and the likelihood of a BRCA1/2 mutation. The cancer 
family history was further classified by lineage as maternal, paternal, both, or no family 
history.
Table 1 illustrates the minimum characteristics used to assign subjects to the elevated- and 
high-risk groups, whereas those subjects not meeting any of these characteristics were 
considered to be at “average” risk. These objective risk categories were based on US 
Preventive Services Task Force designations, other published risk stratification schemes, 
and expert opinion.8,9,11,26
Participants were also asked whether they had discussed their family history of cancer with a 
health-care provider (HCP), had been referred for genetic counseling for cancer risk, and 
had undergone BRCA1/2 genetic testing.
To assess their perceived risk of ovarian cancer, women were asked whether their 10-year 
risk of developing ovarian cancer was much higher, higher, about the same, lower, or much 
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lower than the risk of most women their age. They were also asked whether they thought 
their family history of cancer (any type) greatly increases, somewhat increases, has no 
effect, somewhat decreases, or greatly decreases their risk of cancer. Data collected on 
demographic characteristics included age, marital status, parity, race, education, and income 
level.
We obtained approval for this study from the institutional review boards of the Centers for 
Disease Control and Prevention and HFHS. We also obtained a Certificate of Confidentiality 
under section 301(d) of the Public Health Service Act given the sensitive information we 
were acquiring about personal and family history of cancer and genetic testing. All 
respondents gave consent before conducting the survey interviews.
Statistical analyses
We generated descriptive univariate statistics to evaluate the distribution of demographic 
characteristics (age, race, marital status, education level, income level, and parity) and other 
study variables, including risk group (average, elevated, and high), personal history of breast 
cancer, risk perception measures, and genetics-related health-care activities (having talked 
with an HCP regarding family cancer history, referral for genetic counseling, and 
undergoing genetic testing). In addition, we used Wald χ2 statistics to assess bivariate 
associations between the aforementioned variables and the outcomes of interest: genetic 
counseling and testing. Separate multivariable logistic regression models were used to 
obtain odds ratios (ORs) and 95% confidence intervals (CIs) for genetic counseling and 
genetic testing, which were adjusted by the covariates. We used the Wald χ2 test to assess 
the associations between each outcome and the respective final model covariates, setting 
significance at P ≤ 0.05. We also conducted a logistic regression analysis to obtain crude 
ORs and 95% CIs for genetic counseling referral based on maternal versus paternal cancer 
family history. All estimates were weighted to account for differential selection 
probabilities, including the oversampling of women at high and elevated risk, and for 
nonresponse. We performed all statistical analyses using SAS 9.2 complex survey data 
procedures to account for the stratified sample design.
RESULTS
The distributions of demographic and other characteristics of participants, along with 
complete data for all study variables (n = 2,414), are given in Table 2. The population was 
primarily white, married or partnered, well educated, and in the middle- to upper-income 
brackets. Most had no personal history of breast cancer, were in the average-risk category by 
family history, and were parous. A minority perceived themselves as being at increased risk 
for ovarian cancer, whereas many felt that their family history increased their cancer risks. 
With regard to genetics-related health-care activities, only a small percentage of participants 
had been referred for genetic counseling or had undergone genetic testing, whereas 30% had 
discussed their family history of cancer with their HCP.
Figure 1 illustrates the relationship between the assigned risk categories and the genetics-
related health-care activities in the entire sample. Participants in the high-risk category were 
significantly more likely to have talked with their HCP about their family history of cancer, 
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been referred for cancer genetic counseling, and undergone BRCA testing (P < 0.001 for all 
comparisons). Similarly, those in the elevated-risk group were significantly more likely to 
have participated in these activities than those in the average-risk group (P < 0.001 for all 
comparisons). Nearly 90% of participants at high risk had discussed their family history of 
cancer with their HCP, although only 20% had actually been referred for genetic counseling 
services.
The associations between participant demographic characteristics along with other study 
variables, and individuals who had been referred for genetic counseling (n = 212) and those 
who had undergone BRCA testing (n = 92), were also evaluated in bivariate analysis (Table 
3). Patient age, race, and parity did not appear to be related to receipt of these services, 
whereas annual income, objective risk category, perceived 10-year risk of ovarian cancer, 
personal history of breast cancer, and having talked with an HCP about family cancer 
history were significantly associated with both genetic counseling referral and BRCA testing. 
In addition, genetic counseling referral was highest for women with a graduate degree. 
Marital status, perceived influence of family history on risk, and having been referred for 
genetic counseling were all significantly associated with having undergone BRCA testing.
When analyzed via multivariable analyses (Table 4), several participant characteristics 
continued to significantly influence whether the individual had been referred for genetic 
counseling (n = 212) or undergone BRCA genetic testing (n = 92). In terms of referral for 
genetic counseling, participants with graduate degrees were more than twice as likely to be 
referred for genetic counseling than those with less than or equal to a high school education 
(OR: 2.08; 95% CI: 1.04–4.14). Women in the elevated- and high-risk categories were 2.23 
(OR; 95% CI: 1.41–3.54) and 5.74 (OR; 95% CI: 3.82–8.64) times more likely to be 
referred than those at average risk. Participants who perceived their 10-year risk for ovarian 
cancer as higher than the general population also had a greater than twofold likelihood (OR: 
2.14; 95% CI: 1.34–3.43) of having been referred compared with those who perceived their 
risk to be the same or lower than that of the average woman. Personal history of breast 
cancer was associated with a more than threefold likelihood of referral. This effect was the 
same for both women diagnosed at 50 years of age or younger (OR: 3.10; 95% CI: 2.27–
4.22) and those diagnosed after 50 years (OR: 3.12; 95% CI: 2.12–5.32). Women who had 
spoken with their doctor about their family history reported referral to genetic counseling 
2.4 times more often than those who had not (OR: 2.4; 95% CI: 1.09–5.32).
Somewhat different patterns were seen among women who reported having undergone 
BRCA1/2 testing. Women who were single or had never married were 83% less likely to 
have undergone testing than those who were married or with a partner (OR: 0.17; 95% CI: 
0.07–0.44). Unlike having been referred, perceived risk because of family history strongly 
influenced whether a woman had undergone BRCA1/2 testing. Participants who felt that 
their family history had no effect on their risk were 4.6 (OR; 95% CI: 2.20–9.64) times more 
likely to have undergone testing than those who reported a perceived decreased risk based 
on family history; whereas those who perceived that their family history increased their risk 
were more than 10 times as likely to report having undergone BRCA1/2 testing (OR: 10.44; 
95% CI: 3.89–27.99). Personal history of breast cancer was also associated with testing, 
with ORs of 8.05 (95% CI: 4.99–13.00) and 5.33 (95% CI: 2.20–9.64) for women diagnosed 
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at or younger than 50 years of age and for those older than 50 years of age, respectively, 
compared with women with no personal history. Finally, women who had been referred for 
genetic counseling reported testing at a rate that was almost 13 times that of those who had 
not been referred (OR: 12.94; 95% CI: 7.96–21.04).
Previous research has suggested that a paternal family history of breast and/or ovarian 
cancer is less likely to be identified as a reason for genetic counseling referral with regard to 
BRCA1/2 testing.27 We also found a higher likelihood of being referred for counseling 
among women with a maternal versus paternal cancer family history, although this did not 
reach statistical significance (crude OR: 2.11; 95% CI: 0.99–4.79).
DISCUSSION
Findings from this study offer unique insight into referral for genetic counseling and BRCA 
testing of women from families that are at average, elevated, and high risk as classified 
based on detailed family history information. This large cohort of women is also unique 
because they received care within a system that provides both access to and coverage for 
genetic counseling and testing for HBOC.
Most women reported having talked with their HCP about their family cancer history, 
although this varied significantly by risk category, with almost 90% of those in the high-risk 
group having talked with their provider. By contrast, only 20% of women in the high-risk 
group reported having been referred for genetic counseling. This low referral percentage is 
particularly troubling because this health-care system provides both genetic counseling 
services and coverage for genetic testing. Barriers at the provider level might, in part, 
explain this finding. The literature suggests that failure to identify and refer women at risk 
for HBOC may be ascribed to the lack of time to assess fully familial cancer history,28 lack 
of confidence in knowledge about genetic risk and referral guidelines, and medical 
specialty.29,30 Specific examples of the lack of knowledge about genetics include the failure 
to associate ovarian cancer with breast cancer risk and discounting paternal family history.27 
Although not statistically significant, our data also suggested higher referral patterns among 
women with a family history of cancer in their maternal versus paternal lineage.
In assessing demographic characteristics that potentially influence genetic counseling and 
referral patterns, we found that higher income was not associated with either referral or 
testing when adjusted in multivariable analysis. These findings contradict other studies that 
suggest that patient income is a significant factor.29,31 Our findings might reflect the fact 
that our population tended to be more homogeneous, with higher levels of education and 
income than the general population. Furthermore, these women were in a health-care system 
with regular access to care, which is often not the case for low-income individuals. 
Similarly, education level was not highly predictive: only those with a graduate degree were 
more likely to receive a referral to genetic counseling. Other studies have suggested that 
both education level and knowledge of genetics are associated with endorsement of testing 
or uptake of genetic testing.32,33 Marital status had no effect on referral for genetic 
counseling and only a modest effect on BRCA testing, with those single or never married 
less likely to undergo testing. There was no relationship between parity and either referral to 
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genetic counseling or testing. Race and age, noted in other studies to influence uptake of 
genetic services,34 also did not influence either referral or testing when adjusted for other 
factors. Although risk category strongly predicted referral, it did not appear to influence 
uptake of BRCA testing, possibly because of the low numbers of women undergoing testing, 
particularly in the average- and elevated-risk groups. However, referral for genetic 
counseling was strongly associated (OR: 12.94) with undergoing BRCA testing, likely 
reflecting the protocols for genetic counseling and testing within the HFHS, where 
counseling is typically required for testing to be covered.
Previous data have suggested that younger women without breast cancer but with a positive 
family history express a greater interest in testing than do older women, whereas cancer 
survivors expressing an interest in testing tend to be older.19,21 Our data revealed that age 
impacted neither referral nor testing, although personal history of breast cancer impacted 
both. Although the age of onset of breast cancer (≤50 years vs. >50 years) did not differ in 
terms of influence on referral for genetic counseling, it did strongly influence whether 
women underwent BRCA testing (OR: 8.05 vs. 5.33 compared with women without a history 
of breast cancer). We suspect these differences may reflect the impact of the cancer genetic 
risk assessment and counseling process provided within the HFHS.
We examined two risk perception factors in relation to referral for genetic counseling and 
having undergone BRCA testing: perceived 10-year risk of ovarian cancer and perceived 
influence of one’s family history on risk for cancer. Women with a higher perceived risk of 
developing ovarian cancer in the next 10 years were more than twice as likely to be referred 
for genetic counseling, even when adjusted for objective risk level and other variables, 
including personal history of breast cancer. We also found that a higher level of perceived 
risk of ovarian cancer is suggestive of undergoing BRCA testing, although this association 
did not reach statistical significance. Nonetheless, participants who perceived that their 
family history increased their risk for cancer were substantially more likely to report having 
undergone BRCA testing than those who felt their family history indicated low risk. This is 
consistent with previous publications demonstrating that women with a strong family history 
of cancer21,22,35 and heightened risk perception36 are more likely to express interest in or 
undergo genetic counseling and testing.
We must acknowledge several limitations of our study methodology and data. Most notably, 
our data rely on self-reported accounts of genetic counseling referral, BRCA1/2 testing, and 
family cancer history. To reduce the chances of misreporting, subjects were provided with 
detailed descriptions of these health-care activities as a part of the interview process. 
Because only 0.3 and 4% of survey respondents answered “don’t know” to the questions 
regarding counseling referral and BRCA testing, and no subject refused to answer, any bias 
would be expected to be minimal. With regard to cancer family history, previous studies 
suggest that the accuracy of reporting breast cancer in first-degree relatives is relatively 
high, although this diminishes in the case of second-degree relatives and appears to be less 
reliable for reporting ovarian cancer.37,38 In addition, our exclusion of women with a 
previous history of ovarian cancer or previous oophorectomy possibly led to an 
underestimate of the number of participants at high risk, although ovarian cancer survivors 
comprise less than 0.2% of women aged 30 years or older in the United States.39
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Because there is no single standard for what constitutes “high” versus “elevated” versus 
“average” risk, our results should be considered in the context of our risk classification 
strategy and definition of terms; however, the resulting differences in referral and testing 
patterns suggest that our risk designations matched relatively closely with those determined 
by providers within the system. Notably, however, because we asked about referral for 
genetic counseling and not completion of genetic counseling, we are unable to address 
barriers that may prevent women who have been referred from actually seeking these 
services. Finally, our sample cannot be considered representative of the general population, 
although it is reflective of women within a health-care system that provides access to 
genetics services.
Conclusion
Our results indicate that the availability of cancer genetics services does not, in and of itself, 
lead to appropriate utilization among women at high risk, in part because of underreferral for 
genetic counseling by system HCPs. Classic sociodemographic characteristics appear to 
have minimal impact on receiving a referral for genetic counseling and undergoing BRCA 
testing in this setting of ready access, whereas objective risk category and perception of 
personal and familial cancer risk strongly influence these processes. Our study fills an 
important research gap identified in the recently published US Preventive Services Task 
Force updated recommendations with regard to BRCA— namely the need to evaluate 
referral patterns, risk assessment, and BRCA1/2 testing in settings other than high-risk 
centers.40 Further research is needed to evaluate patient decision making with regard to 
uptake of available genetic counseling and BRCA1/2 testing services, and to evaluate 
interventions targeted toward improving HCP identification and referral of women at high 
risk.
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Figure 1. Genetics-related health-care activities by assigned risk category: discussion of family 
cancer history, referral for genetic counseling, and BRCA testing
*Talked with health-care provider about family cancer history. **Genetic counseling. P < 
0.001 for all comparisons (average versus elevated versus high) for each activity.
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Table 1
Personal and family cancer history features used to assign participants to high- or elevated-risk categories
Category
a High risk Elevated risk
Non-Jewish • 2 FD relatives with br ca, 1 dx ≤ age 50
• 3 Or more FD and/or SD relatives with br ca dx at any age
• 1 FD relative with bilateral br ca
• 1 FD or SD relative with both br ca and ov ca
• 1 FD or SD male relative with br ca
• Personal hx br ca dx ≤ age 50
• 2 FD and/or SD relatives with ov ca
• 1 FD and 1 SD relative with br ca dx ≤ age 50
• 2 Paternal SD relatives with br ca dx ≤ age 50
• 1 FD relative with ov ca
• 2 Maternal SD relatives with br ca dx ≤ 
age 50
• Personal hx br ca dx > age 50
• 2 SD relatives with br ca dx > age 50
• 1 FD and 1 SD relative with br ca, 1 dx ≤ 
age 50
• 1 FD relative with br ca dx ≤ age 50
Jewish • 1 FD relative with br ca
• 1 SD relative with br ca dx ≤ age 50
• 1 FD or SD relative with ov ca
• 2 SD relatives with br ca or 1 with br ca and 1 with ov ca
• FD or SD male relative with br ca
• Personal hx br ca dx any age
• 1 SD relative with br ca dx > age 50
Personal history of ovarian cancer was not included because those with a previous diagnosis were not eligible for the study. If two SD relatives 
were involved, they had to be from the same side of the family.
br ca, breast cancer; dx, diagnosed; FD, first degree; hx, history; ov ca, ovarian cancer; SD, second degree.
a
All other respondents were classified as “average risk.”
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Table 2
Distribution of demographic characteristics, cancer and perceived risk variables, and genetics-related health-
care activities of 2,414 study participants
Characteristic/variable n Weighted (%)
a
Age (years)
 <40 254 13.5
 41–50 566 25.4
 51–60 825 32.1
 61–64 286 10.3
 65+ 483 18.7
Race
 White 1,623 66.0
 Black 653 28.0
 Other 138 6.0
Marital status
 Married/partner 1,621 67.6
 Divorced/separated 365 13.6
 Single/never married 222 10.7
 Widowed 206 8.1
Education level
 ≤High school/GED 732 28.4
 College, <4 years 792 32.6
 College, undergraduate degree 474 20.8
 Graduate degree 416 18.2
Annual income ($)
 <35,000 505 20.2
 35,000–<50,000 415 16.2
 50,000–<75,000 568 23.5
 ≥75,000 926 40.2
Parity
 Yes 2,054 83.9
 No 360 16.1
Assigned risk category
 High 658 7.3
 Elevated 540 6.9
 Average 1,216 85.8
Personal history of breast cancer
 No 2,002 95.1
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Characteristic/variable n Weighted (%)
a
 Yes, diagnosed at age ≤50 years 187 2.1
 Yes, diagnosed at age >50 years 225 2.8
Perceived 10-year risk of ovarian cancer
 Lower 934 46.0
 Same 1,010 41.1
 Higher 470 12.9
Perceived influence of family history on cancer risk
 Decreases 384 22.3
 Has no effect 749 33.3
 Increases 1,281 44.3
Talked to HCP about family cancer history
 Yes 520 29.9
 No 1,894 70.1
Referred for genetic counseling
 Yes 212 4.1
 No 2,202 95.9
Had BRCA1/2 testing
 Yes 92 1.6
 No 2.322 98.4
GED, general educational development (high school equivalency); HCP, health-care provider.
a
Percentages do not always sum to 100% because of rounding.
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Table 3
Relationships between demographic characteristics and other study variables and genetic counseling referral 
and BRCA testing
Referred for genetic counseling (n = 212) Had BRCA1/2 testing (n = 92)
Characteristic/variable Weighted (%) P value Weighted (%) P value
Age (years) — 0.66 — 0.20
 <40 4.0 — <1.0 —
 41–50 3.5 — 1.6 —
 51–60 4.9 — 1.7 —
 61–64 4.2 — 1.0 —
 ≥65 3.7 — 2.5 —
Race — 0.45 — 0.27
 White 4.1 — 1.8 —
 Black 3.6 — 1.4 —
 Other 6.4 — 1.1 —
Marital status 0.35 <0.001
 Married/partnered 4.1 — 1.6 —
 Divorced/separated 3.8 — 2.3 —
 Single/never married 2.9 — <1.0 —
 Widowed 5.7 — 2.7 —
Education level — <0.01 — 0.74
 ≤High school/GED 3.9 — 1.5 —
 College, <4 years 3.6 — 1.5 —
 College, undergraduate degree 2.7 — 1.8 —
 Graduate degree 7.0 — 2.0 —
Annual income ($) — <0.001 — <0.01
 <35,000 3.5 — 2.4 —
 35,000–<50,000 3.6 — <1.0 —
 50,000–<75,000 3.8 — 1.4 —
 ≥75,000 4.8 — 1.8 —
Parity — 0.20 — 0.901
 Yes 4.3 — 1.6 —
 No 3.3 — 1.7 —
Assigned risk category — <0.0001 — <0.0001
 Average 2.3 — <1.0 —
 Elevated 9.1 — 3.5 —
 High 20.4 — 9.6 —
Personal history of breast cancer — <0.0001 — <0.0001
 No 3.1 — 1.0 —
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Referred for genetic counseling (n = 212) Had BRCA1/2 testing (n = 92)
Characteristic/variable Weighted (%) P value Weighted (%) P value
 Yes, diagnosed at age ≤ 50 years 33.2 — 21.4 —
 Yes, diagnosed at age > 50 years 17.0 — 9.5 —
Perceived 10-year risk of ovarian cancer — <0.0001 — <0.0001
 Lower 3.0 — <1.0 —
 Same 3.6 — 1.3 —
 Higher 9.6 — 5.8 —
Perceived influence of family history on cancer risk — 0.14 — <0.0001
 Decreases 2.7 — <1.0 —
 No effect 4.5 — 1.3 —
 Increases 4.5 — 2.6 —
Talked to HCP about family cancer history — <0.0001 — 0.002
 Yes 5.2 — 2.0 —
 No 1.6 — <1.0 —
Referred for genetic counseling — — — <0.0001
 Yes — — 18.8 —
 No — — <1.0 —
Significant findings are displayed in bold.
GED, general educational development (high school equivalency); HCP, health-care provider.
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Table 4




counseling (n = 212)
Had BRCA1/2
testing (n = 92)
OR (95% CI)
Age (years)
 <40 1.00 1.0
 41–50 0.61 (0.31–1.23) 1.30 (0.34–4.86)
 51–60 0.80 (0.37–1.76) 1.13 (0.29–4.30)
 61–64 0.67 (0.26–1.73) 0.82 (0.23–2.90)
 ≥65 0.53 (0.21–1.35) 2.50 (0.48–13.13)
Race
 White 1.00 1.00
 Black 1.07 (0.63–1.81) 1.36 (0.57–3.25)
 Other 1.92 (0.84–4.41) 0.55 (0.29–1.03)
Marital status
 Married/partnered 1.00 1.00
 Divorced/separated 0.79 (0.46–1.37) 1.18 (0.52–2.69)
 Single/never married 0.92 (0.48–1.78) 0.17 (0.07–0.44)
 Widowed 2.02 (0.84–4.87) 1.58 (0.44–5.92)
Education level
 ≤High school/GED 1.00 1.00




0.65 (0.37–1.15) 1.87 (0.40–8.68)
 Graduate degree 2.08 (1.04–4.14) 1.87 (0.44–7.90)
Annual income ($)
 <35,000 1.00 1.0
 35,000–<50,000 0.99 (0.50–1.98) 0.24 (0.10–0.62)
 50,000–<75,000 1.00 (0.47–2.12) 0.43 (0.17–1.08)
 ≥75,000 1.17 (0.58–2.34) 0.48 (0.12–1.81)
Parity
 No 1.00 1.00
 Yes 0.73 (0.43–1.24) 1.77 (0.49–6.82)
Assigned risk category
 Average 1.00 1.00
 Elevated 2.23 (1.41–3.54) 0.67 (0.28–1.63)
 High 5.74 (3.82–8.64) 1.21 (0.53–2.74)
Personal history of breast cancer

















counseling (n = 212)
Had BRCA1/2
testing (n = 92)
OR (95% CI)
 No 1.00 1.00
 Yes, diagnosed at
 age ≤ 50 years
3.10 (2.27–4.22) 8.05 (4.99–13.00)
 Yes, diagnosed at
 age > 50 years
3.12 (2.12–5.32) 5.33 (2.20–9.64)
Perceived 10-year risk of ovarian cancer
 Lower 1.00 1.00
 Same 1.01 (0.59–1.76) 1.32 (0.48–3.62)
 Higher 2.14 (1.34–3.43) 2.93 (0.92–9.32)
Perceived influence of family history on cancer risk
 Decreases 1.00 1.00
 No effect 1.47 (0.68–3.17) 4.61 (2.20–9.64)
 Increases 1.00 (0.50–2.01) 10.44 (3.89–27.99)
Talked to HCP about family cancer history
 No 1.00 1.00
 Yes 2.40 (1.09–5.32) 1.53 (0.48–4.83)
Referred for genetic counseling
 No — 1.00
 Yes — 12.94 (7.96–21.04)
Significant findings are displayed in bold. All variables are included in multivariable logistic regression model.
CI, confidence interval; GED, general educational development (high school equivalency); HCP, health-care provider; OR, odds ratio.
Genet Med. Author manuscript; available in PMC 2015 August 03.
